Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,474 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,543 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04541030 | Integrated Genomic Prostate Score With MRI Targeted Prostate Biopsies | active not recruiting | — | 241 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04577755 | Pomalidomide Treatment in Patients With Kaposi Sarcoma | active not recruiting | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04644770 | A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer | active not recruiting | Phase 1 | 144 | Janssen Research & Development, LLCINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04645160 | Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers | recruiting | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04662580 | ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer(ARX517) | active not recruiting | Phase 1 | 183 | Janssen Research & Development, LLCINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04706663 | Precision-Based Genomics in Prostate Cancer | recruiting | — | 2,000 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04722146 | A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma(MajesTEC-2) | active not recruiting | Phase 1 | 140 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 28, 2026 | clinicaltrials |
| NCT04789694 | Prehabilitation in Gynaecological Cancer Patients(PHOCUS) | recruiting | Phase 3 | 64 | Charles University, Czech RepublicOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04793958 | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | active not recruiting | Phase 3 | 461 | Mirati Therapeutics Inc.INDUSTRY | 32 | Sep 28, 2026 | clinicaltrials |
| NCT04973605 | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 246 | BeOne MedicinesINDUSTRY | 13 | Sep 28, 2026 | clinicaltrials |
| NCT04988295 | A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure(MARIPOSA-2) | active not recruiting | Phase 3 | 776 | Janssen Research & Development, LLCINDUSTRY | 29 | Sep 28, 2026 | clinicaltrials |
| NCT05006716 | A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies(CaDAnCe-101) | recruiting | Phase 1 / Phase 2 | 645 | BeOne MedicinesINDUSTRY | 16 | Sep 28, 2026 | clinicaltrials |
| NCT05015426 | Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT | active not recruiting | Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05025488 | Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm | active not recruiting | Phase 1 | 7 | Marina KremyanskayaOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05050097 | A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma(MonumenTAL-2) | active not recruiting | Phase 1 | 166 | Janssen Research & Development, LLCINDUSTRY | 6 | Sep 28, 2026 | clinicaltrials |
| NCT05100862 | A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma(MAHOGANY) | active not recruiting | Phase 3 | 799 | BeOne MedicinesINDUSTRY | 28 | Sep 28, 2026 | clinicaltrials |
| NCT05112601 | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | recruiting | Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05196087 | Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)(NIP IT!) | recruiting | — | 800 | University Health Network, TorontoOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05256225 | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | recruiting | Phase 3 | 360 | National Cancer Institute (NCI)NIH | 3 | Sep 28, 2026 | clinicaltrials |
| NCT05303467 | A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM(FRONTIER) | recruiting | Phase 1 | 36 | Boston Scientific CorporationINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05388669 | A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer(PALOMA-3) | active not recruiting | Phase 3 | 418 | Janssen Research & Development, LLCINDUSTRY | 20 | Sep 28, 2026 | clinicaltrials |
| NCT05421663 | A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 166 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 28, 2026 | clinicaltrials |
| NCT05424822 | A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | active not recruiting | Phase 1 | 167 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 28, 2026 | clinicaltrials |
| NCT05432804 | Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment | recruiting | Phase 1 / Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05440929 | Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians | recruiting | — | 15 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05498428 | A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer(PALOMA-2) | recruiting | Phase 2 | 520 | Janssen Research & Development, LLCINDUSTRY | 12 | Sep 28, 2026 | clinicaltrials |
| NCT05507827 | Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL | active not recruiting | Phase 1 | 22 | Melody SmithOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05554393 | Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | recruiting | Phase 2 | 153 | National Cancer Institute (NCI)NIH | 3 | Sep 28, 2026 | clinicaltrials |
| NCT05562830 | A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) | recruiting | Phase 1 / Phase 2 | 48 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Sep 28, 2026 | clinicaltrials |
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | recruiting | Phase 2 | 2,900 | National Cancer Institute (NCI)NIH | 2 | Sep 28, 2026 | clinicaltrials |
| NCT05600686 | Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma | active not recruiting | Phase 2 | 24 | University of California, DavisOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05867251 | Study of AVZO-021 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 430 | Avenzo Therapeutics, Inc.INDUSTRY | 2 | Sep 28, 2026 | clinicaltrials |
| NCT05872295 | IKS014 in Advanced Solid Tumors That Express HER2 | recruiting | Phase 1 | 165 | Iksuda Therapeutics Ltd.INDUSTRY | 4 | Sep 28, 2026 | clinicaltrials |
| NCT05903885 | A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans | active not recruiting | N/A | 1,200 | University of NebraskaOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05956093 | 68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study(FAST HOC) | active not recruiting | N/A | 30 | University Health Network, TorontoOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05965999 | Lucid Registry Study(Lucid Registry) | recruiting | — | 8,000 | Lucid Diagnostics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05999877 | PICAROS - Acalabrutinib RWE on 1L CLL in Spain(PICAROS) | recruiting | — | 315 | AstraZenecaINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06031805 | PRostate Olaparib Real World Evidence Study(PROWESs) | active not recruiting | — | 159 | AstraZenecaINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06073821 | Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) | active not recruiting | Phase 3 | 652 | BeOne MedicinesINDUSTRY | 21 | Sep 28, 2026 | clinicaltrials |
| NCT06095089 | A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer | recruiting | Phase 1 | 355 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 28, 2026 | clinicaltrials |
| NCT06110793 | A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06120283 | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 | 433 | BeOne MedicinesINDUSTRY | 11 | Sep 28, 2026 | clinicaltrials |
| NCT06148038 | CBD for Breast Cancer Primary Tumors | recruiting | Phase 1 | 84 | Medical University of South CarolinaOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06149481 | Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) | recruiting | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06252675 | Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma | recruiting | Phase 2 | 30 | University of California, San FranciscoOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06298877 | Frailty, Quality Of Life and Early Reversal of Temporary Defunctioning Stoma in Ovarian Cancer(FOLERO) | recruiting | N/A | 475 | Sahar SalehiOTHER | 1 | Sep 28, 2026 | clinicaltrials |
Data updated 24 hours agoSource updated Sep 28, 2026source: clinicaltrials